CDC/MEC reviews| Volume 94, ISSUE 6, P668-677, December 2016

Co-administration of St. John's wort and hormonal contraceptives: a systematic review



      St. John's wort (SJW) is a known strong inducer of the cytochrome P450 (CYP) 3 A4 enzyme, and both the ethinyl estradiol and progestin components of hormonal contraceptives are substrates of CYP3A4. This systematic review examined whether the co-administration of SJW and hormonal contraceptives leads to significant safety or efficacy concerns.

      Study design

      Systematic review.


      PubMed and Cochrane Library databases were searched for articles of any comparative study design (clinical or pharmacokinetic) that examined potential interactions between SJW and hormonal contraceptives in women of reproductive age.


      Of the 48 identified articles, four studies met inclusion criteria and compared use of combined oral contraceptives (COCs) alone to the use of COCs co-administered with SJW. Two studies demonstrated no change in markers of ovulation, but one study demonstrated increased follicular growth and probable ovulation when COCs were co-administered with SJW. Three studies demonstrated an increased risk of breakthrough bleeding with COCs and SJW. Three studies showed changes in at least one pharmacokinetic parameter that suggested a significantly decreased exposure to hormone concentrations when COCs were co-administered with SJW. The only study that did not demonstrate any significant pharmacokinetic differences examined a SJW product containing a low amount of hypericin.


      Limited evidence showing increased risk of ovulation and breakthrough bleeding raises concern for decreased contraceptive efficacy when COCs are co-administered with SJW. The pharmacokinetic evidence is mixed but suggests that SJW administration may be associated with weak to moderate induction of the metabolism of COCs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wu CH
        • Wang CC
        • Kennedy J
        Changes in herb and dietary supplement use in the U.S. adult population: a comparison of the 2002 and 2007 National Health Interview Surveys.
        Clin Ther. 2011; 33: 1749-1758
        • Tindle HA
        • Davis RB
        • Phillips RS
        • Eisenberg DM
        Trends in use of complementary and alternative medicine by US adults: 1997-2002.
        Altern Ther Health Med. 2005; 11: 42-49
        • Eisenberg DM
        • Davis RB
        • Ettner SL
        • et al.
        Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.
        JAMA. 1998; 280: 1569-1575
        • Samuels N
        • Zisk-Rony RY
        • Zevin S
        • Becker EL
        • Yinnon AM
        • Oberbaum M
        Use of non-vitamin, non-mineral (NVNM) supplements by hospitalized internal medicine patients and doctor-patient communication.
        Patient Educ Couns. 2012; 89: 392-398
        • Cheung CK
        • Wyman JF
        • Halcon LL
        Use of complementary and alternative therapies in community-dwelling older adults.
        J Altern Complement Med. 2007; 13: 997-1006
        • National Center for Complementary and Integrative Medicine
        St John's wort and depression.
        Date: 2003
        (Availabel at:) ([Accessed: December 08, 2015])
        • Izzo AA
        • Ernst E
        Interactions between herbal medicines and prescribed drugs: an updated systematic review.
        Drugs. 2009; 69: 1777-1798
        • U.S. FDA
        Guidance for industry. Drug interaction studies —study design, data analysis, implications for dosing, and labeling recommendations.
        Date: 2012
        (Available at:) ([Accessed: January 20, 2016])
        • Davis SA
        • Feldman SR
        • Taylor SL
        Use of St. John's wort in potentially dangerous combinations.
        J Altern Complement Med. 2014; 20: 578-579
        • Lee CR
        Drug interactions and hormonal contraception.
        Trends in Urology Gynaecology & Sexual Health. 2009; 14: 23-26
        • Yue QY
        • Bergquist C
        • Gerden B
        Safety of St John's wort (Hypericum perforatum).
        Lancet. 2000; 355: 576-577
        • Schwarz UI
        • Buschel B
        • Kirch W
        Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.
        Br J Clin Pharmacol. 2003; 55: 112-113
        • Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom
        St John's wort: interaction with hormonal contraceptives, including implants.
        Date: 2014
        (Available at:) ([Accessed: January 20, 2016])
        • Rahimi R
        • Abdollahi M
        An update on the ability of St. John's wort to affect the metabolism of other drugs.
        Expert Opin Drug Metab Toxicol. 2012; 8: 691-708
      1. MMWR Recomm Rep. 2010; 59: 1-86
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Int J Surg. 2010; 8: 336-341
        • Hall SD
        • Wang Z
        • Huang SM
        • et al.
        The interaction between St John's wort and an oral contraceptive.
        Clin Pharmacol Ther. 2003; 74: 525-535
        • Murphy PA
        • Kern SE
        • Stanczyk FZ
        • Westhoff CL
        Interaction of St. John's wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding.
        Contraception. 2005; 71: 402-408
        • Pfrunder A
        • Schiesser M
        • Gerber S
        • Haschke M
        • Bitzer J
        • Drewe J
        Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.
        Br J Clin Pharmacol. 2003; 56: 683-690
        • Will-Shahab L
        • Bauer S
        • Kunter U
        • Roots I
        • Brattstrom A
        St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.
        Eur J Clin Pharmacol. 2009; 65: 287-294
        • Fogle RH
        • Murphy PA
        • Westhoff CL
        • Stanczyk FZ
        Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills?.
        Contraception. 2006; 74: 245-248
        • Schrager S
        Abnormal uterine bleeding associated with hormonal contraception.
        Am Fam Physician. 2002; 65: 2073-2080
        • Mai I
        • Bauer S
        • Perloff ES
        • et al.
        Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
        Clin Pharmacol Ther. 2004; 76: 330-340
        • Westerhoff K
        • Kaunzinger A
        • Wurglics M
        • Dressman J
        • Schubert-Zsilavecz M
        Biorelevant dissolution testing of St John's wort products.
        J Pharm Pharmacol. 2002; 54: 1615-1621